IN2014MN02126A - - Google Patents

Info

Publication number
IN2014MN02126A
IN2014MN02126A IN2126MUN2014A IN2014MN02126A IN 2014MN02126 A IN2014MN02126 A IN 2014MN02126A IN 2126MUN2014 A IN2126MUN2014 A IN 2126MUN2014A IN 2014MN02126 A IN2014MN02126 A IN 2014MN02126A
Authority
IN
India
Prior art keywords
compounds
calcium
crac
channel
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Nageswara Rao Irlapati
Zubair Abdul Wajid Shaikh
Vijay Pandurang Karche
Gokul Keruji Deshmukh
Neelima Sinha
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Priority to IN2126MUN2014 priority Critical patent/IN2014MN02126A/en
Publication of IN2014MN02126A publication Critical patent/IN2014MN02126A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN2126MUN2014 2012-05-02 2013-05-01 IN2014MN02126A (enExample)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2126MUN2014 IN2014MN02126A (enExample) 2012-05-02 2013-05-01

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN6KO2012 2012-05-02
IN2126MUN2014 IN2014MN02126A (enExample) 2012-05-02 2013-05-01
PCT/IB2013/053440 WO2013164769A1 (en) 2012-05-02 2013-05-01 Substituted pyridine compounds as crac modulators

Publications (1)

Publication Number Publication Date
IN2014MN02126A true IN2014MN02126A (enExample) 2015-09-11

Family

ID=48428565

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2126MUN2014 IN2014MN02126A (enExample) 2012-05-02 2013-05-01

Country Status (7)

Country Link
US (2) US9399638B2 (enExample)
EP (1) EP2844655A1 (enExample)
AU (1) AU2013255437A1 (enExample)
CA (1) CA2871270A1 (enExample)
IN (1) IN2014MN02126A (enExample)
WO (1) WO2013164769A1 (enExample)
ZA (1) ZA201407685B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014203217A1 (en) 2013-06-21 2014-12-24 Lupin Limited Substituted heterocyclic compounds as crac modulators
WO2014207648A1 (en) 2013-06-24 2014-12-31 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
WO2015090579A1 (en) * 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides iv
CN105367547B (zh) * 2014-08-19 2019-04-23 北京桦冠生物技术有限公司 一种噁唑啉酮抗生素的新合成工艺
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
US10525021B2 (en) 2014-11-18 2020-01-07 Rutgers, The State University Of New Jersey Mitochondrial uncouplers for treatment of metabolic diseases and cancer
EP3261641B1 (en) * 2015-02-27 2023-07-12 Calcimedica, Inc. Pancreatitis treatment
CN107847548B (zh) 2015-05-18 2022-06-14 贝思以色列女会吏医学中心公司 P物质、肥大细胞脱颗粒抑制剂和周围神经病
EA034912B1 (ru) * 2015-06-03 2020-04-06 Бристол-Маерс Сквибб Компани 4-гидрокси-3-(гетероарил)пиридин-2-оновые агонисты apj для применения в лечении сердечно-сосудистых заболеваний
CA2995094A1 (en) 2015-08-07 2017-02-16 Calcimedica, Inc. Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
WO2017201313A1 (en) 2016-05-18 2017-11-23 Shengkan Jin Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer
CA3037456A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
IL270224B1 (en) 2017-05-02 2024-04-01 Novartis Ag Combination therapy employing trametinib and a defined raf inhibitor
EP3728230A1 (en) * 2017-12-22 2020-10-28 Ravenna Pharmaceuticals, Inc. Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
PT3762368T (pt) 2018-03-08 2022-05-06 Incyte Corp Compostos de aminopirazina diol como inibidores de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
EP3849552A1 (en) 2018-09-14 2021-07-21 Rhizen Pharmaceuticals AG Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法
CN119421876A (zh) 2022-04-25 2025-02-11 日本新药株式会社 作为ddr1激酶抑制剂的化合物和药物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412805A (pt) 2003-07-23 2006-09-26 Synta Pharmaceuticals Corp método para modular canais de ìon de cálcio ativado por liberação de ìon de cálcio
KR20070057965A (ko) 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
KR20070107022A (ko) 2005-01-07 2007-11-06 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
KR101436161B1 (ko) 2005-01-25 2014-09-01 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
US8802721B2 (en) 2005-01-25 2014-08-12 Synta Pharmaceuticals Corp. Thiophene compounds for inflammation and immune-related uses
US8741960B2 (en) 2006-01-25 2014-06-03 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
AU2007208240B2 (en) 2006-01-25 2013-04-11 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses
TWI417096B (zh) 2006-01-25 2013-12-01 Synta Pharmaceuticals Corp 用於發炎及免疫相關用途之苯基及吡啶基化合物
WO2007089904A2 (en) 2006-01-31 2007-08-09 Synta Pharmaceuticals Corp. Pyridylphenyl compounds for inflammation and immune-related uses
CA2660963A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
TW200911800A (en) 2007-08-01 2009-03-16 Synta Pharmaceuticals Corp Pyridine compounds for inflammation and immune-related uses
HRP20110449T1 (hr) 2007-08-17 2011-07-31 Actelion Pharmaceuticals Ltd. Derivati piridina kao modulatori receptora s1p1/edg1
CA2699157A1 (en) 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2009076454A2 (en) 2007-12-12 2009-06-18 Calcimedica, Inc. Compounds that modulate intracellular calcium
ES2455496T3 (es) 2008-05-23 2014-04-15 Glaxo Group Limited Compuestos tricíclicos que contienen nitrógeno y su uso como agentes antibacterianos
DE102008031299B4 (de) 2008-07-02 2014-10-30 Acandis Gmbh & Co. Kg Filter für ein Blutgefäß
KR101724161B1 (ko) 2008-08-27 2017-04-06 칼시메디카, 인크 세포내 칼슘을 조절하는 화합물
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
US20100130522A1 (en) 2008-10-01 2010-05-27 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2011024004A1 (en) 2009-08-26 2011-03-03 Astrazeneca Ab Heterocyclic urea derivatives useful for treatment of bacterial infection
US8618307B2 (en) 2009-09-16 2013-12-31 Calcimedica, Inc. Compounds that modulate intracellular calcium
NZ609572A (en) 2010-10-30 2015-05-29 Lupin Ltd Oxazoline and isoxazoline derivatives as crac modulators
JP5985611B2 (ja) 2011-05-03 2016-09-06 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連用途のための化合物
WO2013059666A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium

Also Published As

Publication number Publication date
US20160304506A1 (en) 2016-10-20
US9399638B2 (en) 2016-07-26
CA2871270A1 (en) 2013-11-07
EP2844655A1 (en) 2015-03-11
WO2013164769A1 (en) 2013-11-07
ZA201407685B (en) 2015-11-25
US20150111900A1 (en) 2015-04-23
AU2013255437A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
IN2014MN02126A (enExample)
IN2014MN02127A (enExample)
CO6430427A2 (es) Derivados de benzofuranilo
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
GEP20166438B (en) Imidazopyrrolidinone compounds
PH12015500551A1 (en) Tricyclic quinoline and quinoline derivatives
CR20110103A (es) Heteroarilos sustituidos
IN2014CN04907A (enExample)
MD20140109A2 (ro) Compuşi ai indolului şi indazolului care activează AMPK
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX367420B (es) Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
WO2012170931A3 (en) Compounds that modulate intracellular calcium
IN2012DN00943A (enExample)
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
MX337711B (es) Compuestos que modulan el calcio intracelular.
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof
PH12013500831A1 (en) Oxazoline and isoxazoline derivatives as crac modulators
PH12014501979A1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
AU2011322715A8 (en) Treatment of MeCP2-associated disorders
PH12014501891A1 (en) Substituted chroman compounds as calcium sensing receptor modulators
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
WO2012170951A3 (en) Compounds that modulate intracellular calcium
TW201613878A (en) Pyrazine GPR40 agonists for the treatment of type II diabetes
HK1220699A1 (zh) 治疗神经退行性蛋白质病的化合物